Specialist info: Haematology
Explore our latest news, features and educational resources in this specialist area.
Fostamatinib not recommended for refractory chronic immune thrombocytopenia
The cost-effectiveness estimates for fostamatinib compared with rituximab are higher than what NICE normally considers cost effective.
NICE recommends first treatment for rare blood disorder
Midostaurin is reocmmended as a treatment for advanced systemic mastocytosis in adults. It the first targeted therapy for this condition to be available on the NHS.
SMC accepts treatment for primary chronic immune thrombocytopenia
Avatrombopag is accepted for restricted use within NHS Scotland.
NICE publishes new rapid guideline to diagnose and treat rare blood clotting condition associated with COVID-19 vaccination
NICE has today published a new rapid COVID-19 guideline to help healthcare staff identify and treat patients who develop the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) after receiving COVID-19 vaccinations.
SMC accepts treatment for atypical haemolytic uremic syndrome (restricted use)
Treatment with ravulizumab must be under the advice of the national renal complement therapeutics service.
SMC accepts treatment for paroxysmal nocturnal haemoglobinuria
Ravulizumab is accepted for restricted use.
SMC accepts fostamatinib for chronic immune thrombocytopenia
Treatment accepted for restricted use within NHS Scotland.
SMC accepts avatrombopag for severe thrombocytopenia
Avatrombopag is accepted for use within NHS Scotland for severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
Regulatory Alerts, GP info: Blood and immune system conditions, GP info: Musculoskeletal conditions, Specialist info: Haematology
Ferric carboxymaltose (Ferinject▼): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures
Monitor serum phosphate levels in patients treated with multiple high-dose administrations, or those on long-term treatment, and in those with pre-existing risk factors for hypophosphataemia.
